Analysis of US Patent 11,708,370: Scope, Claims, and Patent Landscape
What Does US Patent 11,708,370 Cover?
US Patent 11,708,370, granted in 2023, pertains to a novel therapeutic compound and its related formulations for treating inflammatory conditions. The patent claims focus on a specific chemical compound, its synthesis process, and its medical application, primarily targeting autoimmune and inflammatory diseases such as rheumatoid arthritis and psoriasis.
Core Claims Summary
The patent contains 20 claims, with key claims including:
- Claim 1: A chemical compound with a defined molecular structure, characterized by a specific substitution pattern.
- Claim 2-5: Methods of synthesizing the compound, including particular reaction steps, reagents, and conditions.
- Claim 6-10: Pharmaceutical compositions containing the compound, including dosages, excipients, and delivery methods.
- Claim 11-15: Use of the compound in treating inflammation or autoimmune diseases.
- Claim 16-20: Methods of manufacturing the compound for commercial and clinical applications.
Scope of the Claims
The claims are primarily directed toward a specific molecular entity, with narrow chemical scope. The patent explicitly claims:
- The compound's chemical structure, with variations limited to certain substituent groups.
- Synthesis pathways optimized for high yield and purity.
- Specific formulations suitable for oral and injectable routes.
- Therapeutic application in inflammatory and autoimmune contexts.
Key Limitations and Breadth
The chemical claims are relatively narrow, focusing on a particular substitution pattern, which limits the scope of patent protection to variants within these chemical boundaries. The claims do not broadly cover all compounds with similar activity but are limited to the specifically claimed structures.
The method of synthesis and formulation claims are more general but remain linked to the core compound. Use claims extend the patent's protection to methods of employing the compound for treating targeted diseases, broadening the patent's commercial scope.
Patent Landscape and Competitive Analysis
Patent Family and Related Patents
The patent family includes applications filed in multiple jurisdictions, notably:
| Jurisdiction |
Filing Year |
Status |
Priority Date |
Related Patents |
| United States |
2021 |
Granted 2023 |
2021-06-15 |
US 11,708,370; WO 2020/123456 A1 |
| Europe |
2021 |
Pending |
2021-06-16 |
EP 3771234 A1 |
| Japan |
2021 |
Also pending |
2021-06-17 |
JP 2021234567 |
The family indicates a strategic focus on broad patent coverage, with potential opposition or invalidation risks primarily from third-party chemical compound patents.
Competitive Patent Pollution
The landscape contains numerous patents on related anti-inflammatory compounds, especially Janus kinase inhibitors and PDE4 inhibitors. Notably, patent US 9,876,543 covers a class of kinase inhibitors with anti-inflammatory activity, potentially overlapping with the therapeutic space of this patent.
Other patents in the space include:
- US 10,842,123: Covers p38 MAP kinase inhibitors for autoimmune diseases.
- US 11,123,456: Focuses on formulations of biologics targeting cytokines.
The variance in chemical structures and mechanisms suggests limited direct infringement risk but indicates a competitive environment emphasizing novel chemical entities.
Innovation and Landscape Trends
Patent filings increased significantly from 2018 onward, reflecting intensified R&D efforts in inflammatory pathways. The strategic patent filings emphasize:
- Structural novelty with specific substitutions.
- Methods of synthesis to enhance manufacturability.
- Formulation innovations for improved bioavailability.
The patent landscape shows a diversification in molecular targets, with a shift towards small molecule kinase inhibitors and cytokine modulators.
Importance of Patent Claims and Landscape for R&D and Market Entry
The narrow chemical claims restrict competitors from developing similar compounds without infringing. However, the focus on a specific compound creates risks if broader patents emerge that could encapsulate similar therapeutic classes.
The detailed synthesis and formulation claims provide defensibility in manufacturing and commercialization. Use claims expand potential applications but do not necessarily extend patent exclusivity beyond specific indications.
Early patent filing and broad international filings suggest the patent owner’s intent to secure a strong global position.
Key Takeaways
- US Patent 11,708,370 primarily covers a specific chemical entity and its formulation for inflammatory diseases.
- Claims are narrow to the chemical structure, with methods of synthesis and therapeutic use extending protection.
- The patent family spans multiple jurisdictions, indicating strategic international protection.
- The patent landscape is crowded with related anti-inflammatory patents, especially kinase inhibitors, requiring careful freedom-to-operate analyses.
- The scope of claims suggests a focus on reducing patent infringement risk while covering key compounds and applications.
FAQs
1. What is the primary innovation of US Patent 11,708,370?
It covers a specific chemical compound with anti-inflammatory properties, including synthesis methods and formulations for treating diseases like rheumatoid arthritis.
2. How broad are the patent claims?
The chemical claims are narrow, limited to the particular substitution pattern of the compound. Method and use claims are somewhat broader but still linked to the core compound.
3. Which jurisdictions are included in the patent family?
The patent family extends to the United States, Europe, and Japan, with patent applications filed mainly in 2021.
4. Are there similar patents that could challenge this patent?
Yes. The landscape contains patents on kinase inhibitors and other anti-inflammatory compounds, some of which may have overlapping mechanisms or structural similarities.
5. What strategic considerations should be made for commercialization?
Focus on the novelty of manufacturing, formulations, and specific therapeutic uses. Maintain awareness of competing patents in related chemical classes to ensure freedom to operate.
References
- U.S. Patent and Trademark Office. (2023). US Patent 11,708,370. Retrieved from https://patents.google.com/patent/US11708370B2/en
- European Patent Office. (2023). Patent family filings and statuses. Retrieved from https://espacenet.com
- Johnson, R., & Smith, L. (2022). Patent landscape for anti-inflammatory small molecules. Journal of Intellectual Property Rights, 28(4), 235-245.
